Zyn002 - cbd transdermal gel (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 206 | Fragile X syndrome | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03802799 (ClinicalTrials.gov) | November 9, 2018 | 26/12/2018 | Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS | An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome - CONNECT-FX Open Label Extension (OLE) | Fragile X Syndrome | Drug: ZYN002 - CBD Transdermal Gel | Zynerba Pharmaceuticals, Inc. | NULL | Recruiting | 3 Years | 18 Years | All | 300 | Phase 2;Phase 3 | United States;Australia;New Zealand |
| 2 | NCT03614663 (ClinicalTrials.gov) | June 12, 2018 | 10/7/2018 | Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) | A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome | Fragile X Syndrome | Drug: ZYN002 - CBD Transdermal Gel;Other: Placebo Transdermal Gel | Zynerba Pharmaceuticals, Inc. | NULL | Completed | 3 Years | 17 Years | All | 212 | Phase 2;Phase 3 | United States;Australia;New Zealand |